JPS61122214A - 抗リウマチ剤 - Google Patents

抗リウマチ剤

Info

Publication number: JPS61122214A
Authority: JP; Japan
Prior art keywords: oil; antirheumatic; day; active ingredient; man
Prior art date: 1984-11-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP24564984A

Other languages

English (en)

Japanese (ja)

Other versions

JPS6259091B2 (cs

Inventor

Yuji Maeda

裕司前田

Hideyuki Yamato

英之大和

Takami Fujii

藤井　孝美

Yasuhiko Kobayashi

靖彦小林

Kenichi Saito

健一斉藤

Kenichi Matsunaga

謙一松永

Tadaaki Kato

加藤　侃明

Chikao Yoshikumi

吉汲　親雄

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kureha Corp

Original Assignee

Kureha Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-11-20

Filing date

1984-11-20

Publication date

1986-06-10

1984-11-20 Application filed by Kureha Corp filed Critical Kureha Corp

1984-11-20 Priority to JP24564984A priority Critical patent/JPS61122214A/ja

1986-06-10 Publication of JPS61122214A publication Critical patent/JPS61122214A/ja

1987-12-09 Publication of JPS6259091B2 publication Critical patent/JPS6259091B2/ja

Status Granted legal-status Critical Current

Links

239000003435 antirheumatic agent Substances 0.000 title claims abstract description 8
230000003356 anti-rheumatic effect Effects 0.000 title abstract description 4
239000004480 active ingredient Substances 0.000 claims abstract description 5
FCKJYANJHNLEEP-SRLFHJKTSA-N 24,25-dihydroxycholecalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-SRLFHJKTSA-N 0.000 claims abstract description 4
FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 claims abstract description 3
239000004046 24R,25-dihydroxy-cholecalciferol Substances 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 15
239000003921 oil Substances 0.000 abstract description 5
235000019198 oils Nutrition 0.000 abstract description 5
239000000203 mixture Substances 0.000 abstract description 4
239000002775 capsule Substances 0.000 abstract description 3
239000007900 aqueous suspension Substances 0.000 abstract description 2
239000002285 corn oil Substances 0.000 abstract description 2
235000005687 corn oil Nutrition 0.000 abstract description 2
235000012343 cottonseed oil Nutrition 0.000 abstract description 2
239000002385 cottonseed oil Substances 0.000 abstract description 2
150000002148 esters Chemical class 0.000 abstract description 2
239000008187 granular material Substances 0.000 abstract description 2
239000002904 solvent Substances 0.000 abstract description 2
239000000829 suppository Substances 0.000 abstract description 2
239000003826 tablet Substances 0.000 abstract description 2
244000105624 Arachis hypogaea Species 0.000 abstract 1
239000000428 dust Substances 0.000 abstract 1
230000007935 neutral effect Effects 0.000 abstract 1
235000020232 peanut Nutrition 0.000 abstract 1
239000000126 substance Substances 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
241000699670 Mus sp. Species 0.000 description 3
-1 triglyceride ester Chemical class 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
208000009386 Experimental Arthritis Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000000034 method Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
239000002689 soil Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
235000010199 sorbic acid Nutrition 0.000 description 2
239000004334 sorbic acid Substances 0.000 description 2
229940075582 sorbic acid Drugs 0.000 description 2
210000001562 sternum Anatomy 0.000 description 2
239000004575 stone Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
241000251468 Actinopterygii Species 0.000 description 1
208000031648 Body Weight Changes Diseases 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000000249 Morus alba Species 0.000 description 1
235000008708 Morus alba Nutrition 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
230000004579 body weight change Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
235000001046 cacaotero Nutrition 0.000 description 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000009535 clinical urine test Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
WFDKAKYREYOPOC-UHFFFAOYSA-N ethyl 4-hydroxybenzoate titanium Chemical compound [Ti].C(C)OC(=O)C1=CC=C(O)C=C1 WFDKAKYREYOPOC-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
210000001913 submandibular gland Anatomy 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP24564984A 1984-11-20 1984-11-20 抗リウマチ剤 Granted JPS61122214A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP24564984A JPS61122214A (ja)	1984-11-20	1984-11-20	抗リウマチ剤

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP24564984A JPS61122214A (ja)	1984-11-20	1984-11-20	抗リウマチ剤

Publications (2)

Publication Number	Publication Date
JPS61122214A true JPS61122214A (ja)	1986-06-10
JPS6259091B2 JPS6259091B2 (cs)	1987-12-09

Family

ID=17136778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP24564984A Granted JPS61122214A (ja)	1984-11-20	1984-11-20	抗リウマチ剤

Country Status (1)

Country	Link
JP (1)	JPS61122214A (cs)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103142476A (zh) *	2013-03-21	2013-06-12	青岛正大海尔制药有限公司	骨化三醇混悬剂及其制备方法

1984
- 1984-11-20 JP JP24564984A patent/JPS61122214A/ja active Granted

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103142476A (zh) *	2013-03-21	2013-06-12	青岛正大海尔制药有限公司	骨化三醇混悬剂及其制备方法

Also Published As

Publication number	Publication date
JPS6259091B2 (cs)	1987-12-09

Publication	Publication Date	Title
Schwartz et al.	1953	Metabolic and renal studies in chronic potassium depletion resulting from overuse of laxatives
JPS6089422A (ja)	1985-05-20	抗骨粗鬆症剤
WO1995017889A1 (en)	1995-07-06	Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
EP0136464B1 (en)	1988-10-26	Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
Ellinger et al.	1946	Nicotinamide Deficiency after Oral Penicillin
Abrahams et al.	1947	Fatal Case of Acute Porphyria
EP0276573A2 (en)	1988-08-03	Use of 24,25-dihydroxycholecalciferol in the prophylaxis of bone senescence
Smith	1926	The changes in the vaginal smears were first used for testing an ovarian extract by Allen and Doisey. They have shown that an extract of ovarian follicular fluid will produce changes in the vaginal
JPS61129130A (ja)	1986-06-17	抗尿毒症剤
Czerwinski et al.	1974	Safety and efficacy of zinc sulfate in geriatric patients
KABAKOW et al.	1958	The Effects of Induced Hypocalcemia on Myocardial Irritability and Conductivity: The Use of Disodium Ethylenediaminetetraacetate, with Special Reference to Potassium Depletion, Digitalis Intoxication, and Digitalis-Induced Electrocardiographic Contour Changes
Jenkins et al.	1981	Myopathy induced by rifampicin
Timme	1918	A new pluriglandular compensatory syndrome
JPS6259091B2 (cs)	1987-12-09
JP2543627B2 (ja)	1996-10-16	活性型ビタミンｄ含有治療剤
JP2876547B2 (ja)	1999-03-31	抗クル病剤
JPH0372206B2 (cs)	1991-11-18
JPS6391323A (ja)	1988-04-22	抗尿路結石症剤
JPS5843385B2 (ja)	1983-09-27	シジミの薬効成分及びその製造法
JPS61109721A (ja)	1986-05-28	骨粗しよう症における疼痛軽減剤
Mraz et al.	1995	The role of myocardial glycogen content for the development of isoprenaline-induced myocardial lesions in different inbred strains of rats
JPS61130226A (ja)	1986-06-18	異所性石灰化における疼痛軽減剤
JPS61130227A (ja)	1986-06-18	腫瘍における疼痛軽減剤
Pearl et al.	1977	Propranolol treatment of thyrotoxicosis in a premature infant
SHASKAN et al.	1940	Myeloradiculoneuritis with cell-protein dissociation

JPS61122214A - 抗リウマチ剤 - Google Patents

Info

Links

Landscapes

Priority Applications (1)

Applications Claiming Priority (1)

Publications (2)

Family

ID=17136778

Family Applications (1)

Country Status (1)

Cited By (1)

Cited By (1)

Also Published As

Similar Documents